Create a free account to keep browsing
It takes 30 seconds. You can open three notice pages a day without an account; a free account opens every notice, and lists the ones in your NAICS codes.
2027 NIAID DMID Omnibus Broad Agency Announcement: Development of Medical Interventions for Infectious Diseases
National Institutes of Health · NATIONAL INSTITUTES OF HEALTH NIAID
Respond by: Dec 8, 2026, 3:00 PM UTC−539 days left
From SAM.gov's public data file generated Oct 29, 2026, 3:30 AM UTC; newest notice posted Oct 29, 2026; loaded into FedSub Oct 29, 2026, 5:46 AM UTC
Notice facts
Source: SAM.gov Contract Opportunities public data file
- Solicitation number
- HHS-NIH-NIAID-BAA2026-1
- Notice type
- Solicitation
- Posted
- Oct 9, 2026
- Response date
- Respond by Dec 8, 2026, 3:00 PM UTC−5
- Set-aside
- No Set aside used
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences
- Product or service code
- AN12
- Place of performance
- Not stated
- Contracting office
- NATIONAL INSTITUTES OF HEALTH NIAID (75N930)BETHESDA, MD 20892
- Agency
- Department of Health and Human Services · National Institutes of Health
Past prime awardees
Source: Award history, not a list of bidders on this notice
Past prime awardees · award history, not a list of bidders on this notice
149 companies held prime contracts from this office under NAICS 541715; 43 of them reported first-tier subawards to companies with NAICS 541715 in FedSub's records.
- RESEARCH TRIANGLE INSTITUTE · Reported first-tier subawards to 105 companies with NAICS 541715 in FedSub's records (latest Sep 2026).
24 more past prime awardees on Professional
Description
Source: SAM.gov Contract Opportunities public data file
INTRODUCTION: The National Institute of Allergy and Infectious Diseases (NIAID), one of 27 institutes of the NIH, an agency within the Department of Health and Human Services (DHHS); conducts and supports research to understand, treat, and ultimately prevent the myriad infectious, immunologic, and allergic diseases that threaten the health and longevity of human lives.Through a variety of research grants and contracts, NIAID’s Division of Microbiology and Infectious Diseases (DMID) specifically supports extramural research to develop new medical interventions against infectious disease threats to include drug-resistant pathogens. NIAID/DMID intends to use this BAA to help address goals articulated in a number of strategic plans, such as in the Public Health Emergency Medical Countermeasures Enterprise Strategy and Implementation Plan (https://aspr.hhs.gov/PHEMCE/2024-PHEMCE-SIP/Pages/default.aspx), as well as current prioritized antimicrobial resistant threats identified by national death and infection estimates as determined by the Centers for Disease Control and Prevention’s (CDC) to prevent and control antimicrobial resistance (https://www.cdc.gov/antimicrobial-resistance/data-research/threats/index.html). In addition, NIAID/DMID intends to use this BAA to encourage projects that align with the NIH priorities of enhancing rigor & reproducibility, improving biosafety and biosecurity, and the use of complementary non-animal testing methods where appropriate. This Broad Agency Announcement (BAA) is soliciting proposals to advance the research and development of promising candidate therapeutics, vaccines, and diagnostics for infectious diseases in each of three (3) Research Areas described below and more thoroughly discussed in the attached BAA Solicitation. An offeror should carefully review the content of the BAA Solicitation No. HHS-NIH-NIAID-BAA2026-1 for the comprehensive information regarding all requirements, the technical objective of each Research Area of…
Versions on SAM.gov
Source: SAM.gov Contract Opportunities public data file
Posted Oct 9, 2026SolicitationCurrent version
Respond by Dec 8, 2026, 3:00 PM UTC−5
This version on SAM.gov (opens SAM.gov in a new tab)